<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2022</study_start_year><condition>Adenocarcinoma</condition><condition>Neoplasm Metastasis</condition><condition>Liver Metastasis Colon Cancer</condition><condition>Colon Adenocarcinoma</condition><condition>Liver Neoplasms</condition><condition>Colonic Neoplasms</condition><disease>Adenocarcinoma</disease><disease>Neoplasm Metastasis</disease><disease>Liver Metastasis Colon Cancer</disease><disease>Colon Adenocarcinoma</disease><disease>Liver Neoplasms</disease><disease>Colonic Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2400550</full_dataset_link><location>Italy</location><study_start_month>1</study_start_month><keyword>LDLT</keyword><keyword>Living donor</keyword><keyword>Transplant oncology</keyword><keyword>CRLM</keyword><repository>ECRIN MDR</repository><study_status>Recruiting</study_status></additional><is_claimable>false</is_claimable><name>LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis</name><description>This study is an interventional open label prospective study that aims to assess both overall and disease-free survival of patients treated with LDLT for unresectable CRLM.
Secondary outcomes are graft survival and donor outcomes in terms of safety and quality of life.
Donor selection is performed according to the currently used Institutional and National standards and protocols.</description><dates><creation>2022-01-15</creation></dates><accession>2400550</accession><cross_references><ClinicalTrials___gov>NCT05186116</ClinicalTrials___gov></cross_references></HashMap>